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Abstract
Dengue virus (DENV) is a mosquito-borne pathogen for which no vaccine or specific therapeutic is available. Although it is
well established that dendritic cells and macrophages are primary sites of DENV replication, it remains unclear whether non-
hematopoietic cellular compartments serve as virus reservoirs. Here, we exploited hematopoietic-specific microRNA-142
(miR-142) to control virus tropism by inserting tandem target sites into the virus to restrict replication exclusively in this cell
population. In vivo use of this virus restricted infection of CD11b
+, CD11c
+, and CD45
+ cells, resulting in a loss of virus
spread, regardless of the route of administration. Furthermore, sequencing of the targeted virus population that persisted at
low levels, demonstrated total excision of the inserted miR-142 target sites. The complete conversion of the virus
population under these selective conditions suggests that these immune cells are the predominant sources of virus
amplification. Taken together, this work highlights the importance of hematopoietic cells for DENV replication and
showcases an invaluable tool for the study of virus pathogenesis.
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Introduction
Dengue virus (DENV) is a mosquito-borne flavivirus and the
etiological agent of dengue fever and the more severe clinical
presentations known as dengue hemorrhagic fever (DHF) and
dengue shock syndrome (DSS) [1]. The virus is endemic in tropical
and subtropical regions around the world, and poses a major
global health concern [2]. The four serotypes of DENV (DENV-1,
-2, -3, and -4) are transmitted by Aedes mosquitoes which, given
their global distribution, renders at least 2.5 billion people at risk of
contracting the virus, resulting in as many as 10 million annual
infections worldwide [2,3]. Like other flaviviruses, the DENV
genome is translated into a single polyprotein precursor that is co-
translationally processed by cell- and virus-specific proteases [4].
Virus infection results in the generation of three structural
proteins, C, prM and E, and seven non-structural (NS) proteins,
NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5 [1,4]. Primary
infection of DENV results in mild febrile illness and confers only
partial protection from the remaining serotypes [5,6]. Conse-
quently, a heterotypic secondary infection with a different serotype
can lead to more severe or fatal clinical manifestations such as
DHF/DSS [7]. This pathogenesis feature is referred to as
antibody-dependent enhancement, a phenomenon mediated by
Fc receptors found on cells such as macrophages, neutrophils, and
DCs [5,6,8]. Non-neutralizing antibodies against DENV during a
heterotypic secondary infection allows for infectious immune
complexes to enter Fc-receptor expressing cells and initiate
replication, thereby enhancing virus growth within these cells [6].
DENV replication originates at the site of mosquito inoculation
in resident cutaneous Langerhans dendritic cells (DCs), whose
migration through the lymphatic system results in the induction of
cytokines and the chemokine-mediated recruitment of immune
cells [9,10]. These include monocytes and macrophages, which are
also known to be primary targets of DENV infection [11].
Although it is understood that these cells of hematopoietic lineage
are major sites of DENV replication, it remains uncertain whether
other cells of non-hematopoietic origin are permissive to virus
replication during natural infection. In vitro studies describe a
variety of cell lines of different type and host lineage (human,
murine, monkey, hamster, mosquito) that are permissive to DENV
replication [12]. Furthermore, the virus engages a number of
different receptors including heparan sulfate, DC-specific inter-
cellular adhesion molecule 3-grabbing nonintegrin, CD14, and
heat shock proteins 70 and 90 [13–17]. This broad range of
receptors has led some to propose endothelial cells may be targets
of DENV replication during natural infection [18–20]. However,
the interpretation of these studies has been questioned, as the
presence of viral antigen in endothelial cells could be a result of
virus entry rather than active replication. A counter argument in
support of viral entry, in the absence of replication, is supported by
results that found undetectable levels of viral RNA in endothelial
cells in response to infection [21]. In this study, we sought to
determine the effects of excluding DENV infection from
hematopoietic cells through exploitation of the host microRNA
(miRNA) machinery, and determine whether DENV replication
could still be harbored in the absence of its primary cell targets.
miRNAs are small (18–22 nucleotides (nts)), trans-acting RNAs
that modulate post-transcriptional silencing (PTS) of target genes
by binding to miRNA response elements present in the open
reading frame and/or 39 untranslated regions (UTRs) of target
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Argonaute family, most notably, Argonaute 2 (Ago2), the catalytic
member of the RNA-induced silencing complex (RISC). The
Ago2-containing, miRNA-loaded RISC binds to target mRNA via
the ‘‘seed’’ region of the miRNA (bases 2–7), or through extensive
centered complementarity, resulting in translational repression or
RNA degradation [24–26]. In contrast to miRNAs, short-
interfering RNAs (siRNAs) bind with perfect complementarity
and disrupt target expression levels more effectively through Ago2-
mediated cleavage of the messenger RNA transcript [22,27–30]. It
therefore follows that incorporation of fully complementary
miRNA target sites into a virus can effectively convert an
endogenous miRNA into a virus-specific ‘‘siRNA’’. This concept
has been successfully demonstrated for a number of viruses,
including influenza A virus, poliovirus, vesicular stomatitis virus,
and measles virus [31–39]. In addition, DENV itself has been
rendered susceptible to a miRNA, but only in the context of a
replication-incompetent replicon or as a chimera with tick-borne
encephalitis virus structural proteins [37,40].
In an effort to exclude DENV selectively in immune cells, we
incorporated perfect hematopoietic-specific miRNA target sites
into the 39 UTR of the virus to serve as a tool to study DENV
replication in non-hematopoietic cells in vivo. We demonstrate that
miR-142 targets can confer cell-specific attenuation in both in vitro
and in vivo assays, and that hematopoietic cell types, such as
monocytes, DCs, and macrophages, are required for DENV
growth and dissemination during natural infection.
Results/Discussion
Before designing a method of exploiting miRNA machinery to
suppress DENV replication, we sought to confirm DENV
infection does not block miRNA biogenesis or function. To assess
effective knockdown of a miRNA target, human fibroblasts
expressing a green fluorescent protein (GFP) targeted by miR-
142 (pEGFP-142t) were transfected with either vector or a plasmid
expressing miR-142 (p142), a miRNA normally absent in these
cells. In uninfected cells, expression of miR-142 resulted in a
dramatic reduction of visible GFP expression (Figure 1A), equating
to a 75% loss of fluorescence (Figure 1B). Furthermore, despite a
multiplicity of infection (MOI) that would ensure high levels of
virus replication, verified by quantitative RT-PCR (qRT-PCR)
(Figure 1C), the presence of DENV-2 did not alter the efficiency of
miR-142-mediated PTS. In accordance with the lack of DENV-2-
mediated disruption of miR-142-targeting, northern blots for the
expression of other exogenous (miR-124) and endogenous (miR-
93) miRNAs also demonstrated no discernable differences during
virus replication (Figure S1). Taken together, these results suggest
DENV-2 does not interfere with miRNA-mediated PTS or
miRNA biogenesis, and that cellular miRNA machinery may be
exploited for DENV targeting.
During natural infection, DENV displays tropism for cells of
hematopoietic lineage, specifically, monocytes, macrophages and
DCs [9,11,36,41,42]. As miR-142 is one of the most abundant
hematopoietic-specific miRNAs [43,44], it served as an ideal
candidate for mediating cell-specific attenuation. To generate a
DENV-2 strain that demonstrated miR-142-susceptibility, we
incorporated four target sites into the 39 UTR of the virus
(Figure 2A). Given the highly structured secondary conformations
important for both transcription and translation in the 39 UTR
[45,46], we incorporated the target sites downstream of the NS5
coding frame, in the variable region believed to be more amenable
to nt insertions [46] (Figure S2). Following construction of both a
miR-142-targeted (142t) virus and a parental control (ctrl) virus,
encoding reverse target sites, we next sought to determine their
replicative properties in cells lacking miR-142. To this end, we
performed multi-cycle growth curves in mosquito Aedes Albopictus
larvae cells (C6/36) and baby hamster kidney (BHK) cells, neither
of which express miR-142 (Figure 2B). By qRT-PCR and western
blot, both ctrl and 142t strains grew to similar levels in C6/36 cells
(Figure 2C) reaching equal growth at 84 hrs post infection (hpi),
but demonstrating an approximate one-log reduction as compared
to wild type, unmodified virus (wt). This data was further validated
by plaque assay, demonstrating peak titers of ,1610
3 PFU/mL
for both ctrl and 142t viruses as compared to ,1610
4 PFU/mL
for wt virus (Figure S3). Furthermore, experiments in BHK cells,
another cell devoid of miR-142, demonstrated peak virus loads at
48 hpi, a time at which cytopathic effects reduced overall titers
and NS5 expression (Figure 2D). Consistent with the data from
C6/36 cells, wt virus exceeded both ctrl and 142t strains,
suggesting that the 157 nt insertion lowered the overall fitness of
the virus, independent of sequence.
To determine whether DENV-2 transcripts could be targeted
by the miRNA machinery, we first attempted to see whether the
presence of miR-142 could prevent virus production from the in
vitro transcription (IVT) of the 142t cDNA clone. BHKs,
expressing vector or p142, were electroporated with IVT products
from wt, ctrl, or 142t DENV-2 cDNA clones. Twenty-four hrs post
transfection (hpt), miR-142 production was evident by northern
blot, albeit lower than observed in bone-marrow derived primary
macrophages (BMMs) (Figure 3A). Given the production of miR-
142, we evaluated NS5 protein levels from the IVT product to
determine the degree of transcript targeting (Figure 3B). Consis-
tent with previous work demonstrating miRNA-mediated virus
attenuation [31], NS5 expression derived only from 142t IVT
product was abrogated in a miRNA-specific manner (Figure 3B).
This result would suggest that virus synthesis from the 142t IVT
product was blocked in the presence of miR-142.
Next, we sought to determine whether miR-142 could attenuate
142t in the context of infection. To this end, fibroblasts expressing
vector or p142 were infected with wt, ctrl, or 142t strains, and
assessed for virus products. As evident by NS5 expression, miR-
142 abolished replication of the 142t strain, while exuding no
impact on wt or ctrl strains (Figure 3C). It is noteworthy that
Author Summary
Dengue virus (DENV) is becoming a global threat as
anthropogenic factors are increasing the prevalence of
vector species capable of transmitting the pathogen. There
are currently no vaccines or therapeutics against DENV,
and the study of virus pathogenesis and dissemination has
been largely limited to artificial mouse models. As DENV is
capable of infecting many cell types including dendritic
cells (DCs), macrophages, and fibroblasts, it remains
unclear which cells permit DENV replication in vivo and
are responsible for virus spread. To this end, we inserted
microRNA (miRNA) target sites into the virus genome to
render it incapable of replicating in DCs and macrophages,
while having no direct effect on replication in other cell
types. The purpose of this study was to exclude virus
growth in a defined cellular population and assess the
effects of this restriction on viral dissemination and
replication in vivo. With this technology, we demonstrate
that restricting replication in hematopoietic cells results in
a complete loss of miRNA-targeted virus, indicating that
these cells are the predominant reservoirs for virus
replication.
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cells not successfully transfected with p142, a constraint that would
not be in place during an endogenous infection of a hematopoietic
cell. Taken together, these data clearly demonstrate that insertion
of miRNA target sites into the 39UTR of DENV-2 renders the
virus susceptible to miRNA expression.
In an attempt to ascertain the mechanism underlying miR-142-
mediated attenuation, we modified the miR-142 target sites to
render the DENV genome resistant to canonical miRNA binding
and Ago2 cleavage. To this end, the nucleotides complementary to
positions 3 and 10 of miR-142 were mismatched in the virus
targets to destroy the seed sequences and cleavage sites,
respectively [47]. To assess whether this mutated 142t strain,
herein referred to as 142tm, was targeted by miR-142, we
compared NS5 synthesis in the presence and absence of the target
miRNA (Figure 3D). Surprisingly, virus production from the
142tm strain was still abrogated in a miR-142-specific manner,
despite harboring two critical mismatches in the miRNA targeting
sites. As loss of NS5 in the 142tm strain maintained miR-142-
specificity, these results would suggest that RISC was still engaging
on the mutated targets in a non-canonical manner, perhaps as a
result of the remaining extensive complementarity. To determine
the underlying mechanism responsible for attenuation of the
142tm strain, we examined the levels of genomic viral RNA to
discern between RNA degradation and translational inhibition.
Quantitative RT-PCR analysis demonstrated that, at the level of
RNA, the amount of miR-142-mediated repression of the 142tm
virus was significantly (p=0.0178) lower than that of 142t,
suggesting the mode of attenuation may no longer be RNA
cleavage, but may involve a form of translational repression
(Figure 3E). This translational repression could be the result of
extensive 39 miRNA complementarity acting in a canonical
manner or could be the result of miR-142/RISC sterically
blocking the association of the 59 and 39 ends, preventing
cyclization and amplification of the virus genome. While future
studies will be required to ascertain the exact mechanism of 142tm
attenuation, these data strongly demonstrate that inhibition of
virus replication occurs in a miR-142-dependent manner. As the
142tm virus showed decreased silencing activity, subsequent
characterization focused only on the comparison between ctrl
and 142t strains.
As cells of hematopoietic lineage are the natural sites of DENV
infection and express high levels of miR-142 (Figure 3A) [1,44], we
aimed to determine whether we could observe differential cell-
specific attenuation between the ctrl and 142t strains. To this end,
we compared infections of the recombinant DENV-2 strains in
two hematopoietic lineages, B cells and BMMs, as well as a non-
hematopoietic fibroblast lineage, HEK293s (Figure 3F). Consistent
with exogenous targeting by miR-142, infection of hematopoietic
cell types demonstrated selective attenuation of the 142t strain,
while infection of the non-hematopoietic cells demonstrated no
change in NS5 levels between ctrl- and 142t-virus infected samples
(Figure 3F). Taken together, these data demonstrate that the
incorporation of miR-142 target sites into the 39UTR of DENV-2
confers endogenous attenuation of the virus in a cell-specific
manner.
As human DENV isolates currently lack an adequate animal
model that recapitulates human pathogenesis during infection, we
chose Ifnar1
2/2/Il28r
2/2 mice to investigate our recombinant
viruses in vivo. These mice lack the ability to respond to type I and
III interferon and are, thus, more susceptible to virus infection
[48,49]. To ensure that the in vitro and ex vivo data reflected in vivo
attenuation, we first infected mice with ctrl and 142t viruses and
isolated CD11b
+ and CD11c
+ macrophages and DCs, respectively
(Figure 4A). qRT-PCR analysis of RNA derived from these cells
demonstrated minimal detection of NS5 transcripts derived from
the 142t strain and a significant decrease compared to ctrl virus.
These data support our in vitro data, where 142t virus replication is
excluded in hematopoietic cell types.
To examine in vivo replication of the 142t virus in non-
hematopoietic compartments, we sorted splenocytes from infected
mice for CD45-expressing cells, and assessed viral gene expression
in each population (Figure S4A). The nature of this experiment
however is complicated by the fact that, should hematopoietic cells
be required for virus dissemination, we would anticipate lower
virus titers in non-hematopoietic fractions as well. As anticipated,
142t virus growth was attenuated in the CD45
+ hematopoietic
fraction. In addition, the CD45
2, non-hematopoietic fraction
demonstrated a decrease in 142t virus growth as compared to ctrl,
supporting that dissemination of the virus is dependent on its
ability to replicate in hematopoietic cell types. To account for this
lack of dissemination, we compared the relative level of virus
growth between hematopoietic and non-hematopoietic popula-
tions, and determined that the 142t virus displayed enhanced
replication in CD45
2, non-hematopoietic cells (Figure 4B). Taken
together, these data suggest that the 142t virus is not attenuated in
Figure 1. DENV-2 does not block miRNA function. (A) Fluorescence microscopy of human fibroblasts cotransfected with a plasmid expressing
GFP targeted by miR-142 (pEGFP-142t) and either a construct expressing miR-142 (p142) or an empty vector control (vector). Cells were mock treated
or infected with DENV-2 at an MOI of 1 48 hrs prior to analysis. (B) Fluorescence-activated cell sorting of samples treated as in (A). (C) Quantitative RT-
PCR on samples described in (A). Data depicted as NS5 over tubulin levels. (Statistical significance: ****, P,0.0001, ***, P,0.001).
doi:10.1371/journal.ppat.1002465.g001
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decreased hematopoietic replication.
Following verification of in vivo targeting, we further assessed
dissemination of the ctrl and 142t strains in Ifnar1
2/2/Il28r
2/2
mice. To this end, three different routes of inoculation were
administered to assess virus replication in both liver and spleen.
Different cohorts of mice were administered virus by either
intraperitoneal (IP), intraveneous (IV), or subcutaneous (SC)
injection (Figure 4C, Figure S4B). For IP administration, qRT-
PCR analysis of the spleen revealed an ,1.5-log reduction in viral
transcript levels of the 142t strain as compared to those given ctrl
virus (Figure 4C). This attenuation was further enhanced by IV
and SC injection, routes that better simulate natural inoculation.
Interestingly, decreased amounts of NS5 transcript was also
evident in the liver (Figure S4B), where miR-142 expression is
reduced compared to the spleen [50]. Taken together, these in vivo
results suggest that virus levels in the liver reside predominantly in
resident macrophages and DCs, and that perhaps these cells are
needed to maintain basal levels of virus replication in non-
hematopoietic cells. To further validate the reduction of viral
growth in vivo, viral titers from infected mice corroborated qRT-
PCR data by demonstrating an approximate three-log reduction
in titers from spleen and liver (Figure 4D, Figure S4C). Viral titers
were undetectable in heart, lung, and brain from these mice,
demonstrating that the spleen and liver were the primary sites of
virus replication in the context of this animal model.
As low levels of 142t virus were evident in both the spleen and
the liver, we next sought to determine whether this reflected a non-
Figure 2. Generation and characterization of miR-142-targeted DENV-2. (A) Cloning strategy for the insertion of miR-142 target sites into
the 39untranslated region (UTR) of a T7-driven DENV-2 cDNA clone. A 157 nucleotide (nt) insert containing four tandem target sites were cloned into
the variable region of DENV-2 (142t virus). A control (ctrl) virus containing four reverse sites is also depicted. (B) Northern blot for miR-142 expression
in Aedes albopictus mosquito (C6/36) cells, mammalian baby hamster kidney cells (BHKs), murine bone-marrow-derived macrophages (BMMs), and a
human B cell line (Raji). (C) Quantitative RT-PCR and western blot analysis on C6/36 cells infected with wt, ctrl, and 142t viruses at the indicated time
points. Wild type (wt) virus refers to a clone encompassing no modifications. (D) Same as described in (C) for BHK cells.
doi:10.1371/journal.ppat.1002465.g002
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of virus escape. In an effort to characterize the genotype of the
recombinant DENV viruses over the course of infection, we
amplified the 39UTR of the ctrl and 142t viruses derived from in
vitro and in vivo infections (Figure S5 and Figure 5A). To this end,
non-hematopoietic fibroblasts expressing varying levels of miR-
142 were infected for 39UTR sequence analysis. In vitro, 142t-
specific transcripts were only detectable in conditions where miR-
142 expression was decreased, a result that could reflect lower
transfection efficiency or insufficient miRNA levels. To assess the
39UTR sequence in vivo, splenocytes from infected mice were
analyzed, demonstrating abundant transcript levels of the ctrl virus
and significantly lower levels of the 142t virus (Figure 5A).
Furthermore, the only product derived from the 142t virus
migrated faster during gel electrophoresis, suggesting it had been
truncated. Sequence analyses of transcripts from these two
infections demonstrated an unbiased mutation frequency in vitro
that was comparable between the two viral cohorts, suggesting the
mutations were a reflection of low polymerase fidelity, rather than
a result of evolutionary constraint. In contrast, sequence analyses
of the transcripts found in vivo demonstrated a complete absence of
142t virus. Rather, virus species remaining displayed loss of all
Figure 3. In vitro knockdown of miR-142-targeted DENV-2 during exogenous and endogenous miR-142 expression. (A) Northern blot
confirming exogenous expression of miR-142 by plasmid transfection. BHKs and HEK293s were transfected with vector or p142 and analyzed 24 hrs
post transfection (hpi). Bone marrow-derived macrophages (BMMs) were included as a positive control for miR-142 expression. (B) Western blot for
NS5 and actin expression in BHKs transfected with vector (2) or p142 (+) and treated with wt, ctrl, or 142t in vitro transcription (IVT) products. (C)
BHKs treated as in (B) were infected with wt, ctrl, or 142t viruses and analyzed as in (B). (D) Western blot for NS5 and actin expression in BHKs treated
as in (B) with wt, ctrl, 142t, or 142tm IVT products. (E) Quantitative RT-PCR on DENV-2 transcript in BHKs treated as in (B) with ctrl, 142t, or 142tm IVT
products. (F) Western blot for NS5 and actin expression in hematopoietic cells (Raji B cells and BMMs) and non-hematopoietic fibroblasts (HEK293s)
infected with the indicated recombinant DENV-2 strains.
doi:10.1371/journal.ppat.1002465.g003
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replacement with a small host RNA fragment (Figure 5B). The
sequence analysis performed here explains why low levels of 142t
virus was detected by qRT-PCR in Figure 4, as this assay
measured levels of NS5, which encompasses any escape mutants
present during infection. Our data in Figure 5 reveals that the
percentage of 142t virus represented is, in fact, much lower.
Furthermore, this is unlikely attributable to the presence of quasi-
species in our virus stocks, as these mutations were not observed in
vitro (Figure S5B).
Previous efforts aimed at defining the tropism of DENV
infection have focused on the detection of virus components in
various tissues of the host. Unfortunately, distinguishing between
active DENV replication within a cell versus the presence of virus
due to cellular engulfment has been difficult. Here we take an
innovative approach to addressing this question with the
generation of a virus that is selectively attenuated in a cell-type
specific manner. Through the exploitation of hematopoietic-
specific miR-142, we were able to exclude the replication of
DENV at its major sites of replication in vivo, and demonstrate that
these cell populations are critical for dissemination of the virus to
other tissues. Our initial in vitro work clearly demonstrated the
specificity of the system and provided a foundation for the
subsequent studies performed in mice. The technology enabled a
precise mechanism to eliminate primary target cells of DENV
replication and study the effects in the context of a dynamic in vivo
infection.
An additional noteworthy finding that resulted from this study
centers on the mechanism of miRNA-mediated attenuation. While
attenuation of the 142t strain is presumably the result of target
RNA cleavage by Ago2, the repression of 142tm is an enigma. The
data supports that 142tm attenuation occurs less at the level of
RNA than it does at the level of protein, making the underlying
molecular biology responsible for this repression unclear. While
the extensive complementarity may be responsible for some level
of post-transcriptional silencing, the complete loss of the seed
sequence makes this unlikely. An alternative hypothesis would be
that the level of complementarity is sufficient to recruit miR-142-
containing RISC, but not sufficient to confer post- transcriptional
silencing. In this model, RISC-binding may do nothing more but
provide a steric hinderance to the virus. To undergo replication,
DENV, as well as other flavivirus genomes, cyclize through
complementarity at conserved elements in the 59 and 39 ends of
the viral RNA [51]. As such, RISC function may be at the level of
physically disrupting proper folding of the virus genome. This
latter model is supported by the isolation of escape mutants.
Figure 4. In vivo knockdown of miR-142-targeted DENV-2. (A) Quantitative RT-PCR (qRT-PCR) on NS5 and tubulin from CD11b
+ and CD11c
+
cells from splenocytes of Ifnar1
2/2/Il28r
2/2 mice inoculated with either ctrl or 142t strains via intravenous (IV) injection. (B) qRT-PCR for DENV capsid
in CD45
2 versus CD45
+ splenocytes represented as a ratio for ctrl and 142t virus infections in Ifnar1
2/2/Il28r
2/2 mice. (C) qRT-PCR on spleens from
Ifnar1
2/2/Il28r
2/2 mice infected intraveneously (IV), intraperitonealy (IP), and subcutaneously (SC) for 48 hrs. (D) Viral titers from spleens of Ifnar1
2/2/
Il28r
2/2 mice infected as in (A) for 24, 48, and 72 hpi. (Statistical significance: *, P,0.05, **, P,0.01) Each data point represents an individual animal.
doi:10.1371/journal.ppat.1002465.g004
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center sites of each target, the only escape mutants isolated were
viruses in which the complete targeting cassette was excised.
Taken together, this suggests that miRNA-mediated attenuation of
viruses may be occurring both through transcriptional silencing,
and through the steric interference of RNA folding. Future work to
address this possibility is ongoing.
In closing, this technology has become a unique and effective
tool to study cell populations involved in the DENV life cycle, and
can be easily applied to other viruses to examine the relevance of
cellular subsets involved in virus replication. In this regard, it is
interesting that restricting hematopoietic replication of DENV-2
prevents overall dissemination of the virus suggesting that non-
hematopoietic primary cells may not be productively infected in
vivo or that macrophages and DCs are essential for viral spread.
Altogether, the successful attenuation of DENV in a cell-specific
manner suggests this technology may be exploited for studying the
relative contributions of cell subsets to virus pathogenesis in vivo.
Materials and Methods
Ethics statement
All animal studies were approved by the Animal Care and Use
Committee of Mount Sinai School of Medicine and were
performed in compliance with relevant institutional policies, the
Association for the Accreditation of Laboratory Animal Care
guidelines, the National Institutes of Health regulations, and local,
state, and federal laws.
Plasmid construction and virus rescue
A full-length infectious cDNA clone of DENV-2 (16681), pD2/
IC-30P-A, was used as a template for site-directed mutagenesis
(SDM) to introduce a unique AflII restriction enzyme site for
subsequent insertion of miR-142 target sites into the 39 NCR [52].
The pD2/IC-30P-A construct was a kind gift from Richard
Kinney (Arbovirus Disease Branch, CDC, Fort Collins, CO). The
AflII site was generated with complementary SDM primers
resulting in the following sequence: 59-TAGAAAGCTTAAG-
TAACATGAAA-39 (AflII site is underlined). Target sites for miR-
142 have been described elsewhere [53] and were cloned into the
AflII sites in both the forward (142t DENV-2) and reverse (ctrl
DENV-2) orientations. For the 142m strain, the following
complementary oligonucleotides were annealed and cloned into
the AflII site: Forward 59-GGCTTAAGTCCATAAAGTAGG-
CAACACTCCAAGGCGATCCATAAAGTAGGCAACACTC-
CAGCGGCCGCTCC-39, Reverse 59- CCCTTAAGTGGAGT-
GTTGCCTACTTTATGGAGAGCCCTGGAGTGTTGCCTA-
CTTTATGGAGCGGCCGCTGG -39. Recombinant pD2/IC-
30P-A clones were linearized with XbaI, in vitro transcribed with
T7, and electroporated into BHK cells as previously described
[52]. Viral titers were determined by 1% agarose-based plaque
assays performed in Vero cells.
Fluorescence-activated cell sorting
Transfected and infected HEK293s were harvested 48 hpi and
analyzed for GFP fluorescence on the Becton Dickinson FACS
Caliber and mean fluorescence intensity was calculated using the
Flowjo analysis software. Experiments were performed in triplicate
and mean fluorescence intensity for GFP was calculated as a
percentage of the vector control.
Cell culture, infections, and plaque assays
Unless otherwise specified, all mammalian cell lines were
cultured in DMEM/FBS. C6/36 cells were cultured in RPMI
Figure 5. In vivo escape mutants of miR-142-targeted DENV-2. (A) RT-PCR on spleen samples from Ifnar1
2/2/Il28r
2/2 mice infected with either
ctrl or 142t viruses. (B) Mutations identified in Ifnar1
2/2/Il28r
2/2 mice infected with ctrl and 142t viruses. Depicted mutations map to miR-142
complementary sites in the targeted and untargeted orientations. Notations in red designate nucleotide changes.
doi:10.1371/journal.ppat.1002465.g005
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infected with either wt, ctrl, or 142t DENV-2 at an MOI of 1 in
serum-free DMEM. The inoculum was allowed to adsorb for two
hrs at 37uC, washed and replaced with DMEM (5% FBS).
Infection for plaque assays were performed as described above in
BHKs in duplicate with 1:10 serial dilutions of virus stocks.
Infected mouse organs were harvested and homogenized in 16
PBS, and frozen at 280uC prior to plaque assay. After 2 hrs of
adsorption, an overlay of 1% agarose/DMEM was added to the
cells and allowed to incubate for 6 days at 33uC. Cells were stained
using 1% crystal violet.
Transfection and electroporation
Cells were transfected in suspension using Lipofectamine 2000
for HEK293s (Invitrogen) and Lipofectamine LTX (Invitrogen) for
BHKs as per manufacturer’s instructions. For studies involving
knockdown of DENV IVT products, BHKs were transfected with
vector or p142 for 24 hrs, followed by electroporation of DENV-2
IVT products for 12 (Figure 3E), 24 or 48 hrs with the Amaxa
nucleofector (Lonza) as per manufacturer’s instructions. For virus
rescue, 5610
6 BHKs were electroporated with DENV-2 IVT
products and seeded into 10 cm plates. Six days post electropo-




2/2 mice have been described elsewhere [48].
Mice were given 2610
6 PFU for IP, 4610
5 PFU for IV, and
2610
5 PFU for SC injections. Indicated organs were removed
from animals 48 hpi. All experiments involving animals were
performed in accordance with the Mount Sinai School of
Medicine Institutional Animal Care and Use Committee.
Magnetic-activated cell sorting
Spleens from infected Ifnar1
2/2/Il28r
2/2 mice were processed
into single cell suspensions and stained with anti- CD11b (Miltenyi
Biotech), CD11c (Miltenyi Biotech), or CD45 microbeads
(Miltenyi Biotech). Positive and negative cell fractions were
isolated using autoMACS Pro Separator (Miltenyi Biotech)
followed by RNA isolation.
Western blot and qRT-PCR analysis
Protein and RNA cellular extract were harvested as previously
described (Perez et al, 2009). NS5 antibody (anti-NS5, rabbit
polyclonal, a kind gift from A. Garcia-Sastre) and actin (anti- actin,
Abcam,) were used at a concentration of 1 microgram per milliliter
in 5% milk. Secondary rabbit or mouse antibodies (GE
Healthcare) were used at 1:5000 dilutions for 1 hr at room
temperature. Immunobilon Western Chemiluminescent HRP
Substrate (Millipore) was used as per manufacturers instructions.
Quantitative RT-PCR (qRT-PCR) analysis was performed with
random hexamers using Superscript II (Invitrogen) and cDNA
samples was performed using KAPA SYBR FAST qPRC Master
Mix (KAPA Biosystems). PCR reactions were performed on a
Mastercycler ep realplex (Eppendorf). a-Tubulin and actin
primers were used as endogenous housekeeping genes for
mammalian and mosquito cultures, respectively. Delta delta cycle
threshold (DDCT) values were calculated with replicates over a-
tubulin or actin. Values represent the fold change over mock-
infected samples. Sequences for PCR primers used: NS5: 59-
ACAAGTCGAACAACCTGGTCCAT-39,5 9-GCCGCACCAT-
TGGTCTTCTC-39, a-tubulin: 59-TGCCTTTGTGCACTGG-




and DENV 39UTR: 59- TCCCTTATAGGCAATGAAGAA-
TACA-39,5 9-TTATGATGGCCTGACTTCTTTTAAC-39.
Sequencing of escape mutants
cDNA from BHKs transfected with 1.5 micrograms of p142 and
infected with either ctrl or 142t viruses for 24 hrs was reverse
transcribed with random hexamers using Superscript II (Invitro-
gen). Virus transcript was PCR-amplified with Econotaq PLUS
green (Lucigen) using primers specific for the 39UTR of DENV:
forward 59-TTTGGGGAAGTCTTACGC-39, reverse 59-GTT-
GCTGCGATTTGTAAGG-39. Hamster actin primers were
included as a loading control: forward 59-TCTACAACGAG-
CTGCG-39, reverse 59-CAATTTCCCTCTCGGC-39. Twenty
PCR cycles were performed with the following conditions: 94uC
for 10 sec, 58uC for 30 sec, 72 for 1.5 min. Bands were gel
purified using the Qiagen gel extraction kit and cloned into pCR-
TOPO 2.1 (Invitrogen) following manufacturer’s protocols. Fifteen
random clones were submitted for sequencing with the M13R
primer. Sequences were then aligned to miR-142 complementary
sites in the targeted and untargeted orientation. Mutations
identified in these regions were noted. For escape mutants found
in vivo, reverse transcription was performed on cDNA from spleens
of Ifnar1
2/2/Il28r
2/2 mice infected with ctrl or 142t viruses for
48 hrs. PCR was performed as described above for 40 cycles.
Bands were gel purified and cloned as described above.
Small RNA northern blot analysis
Small RNA northern blotting and probing were performed on
total RNA samples as described previously (Perez et al, 2009).
Probes include: miR-142: 59- TCCATAAAGTAGGAAACAC-
TACA-39, U6: 59-GCCATGCTAATCTTCTCTGTATC -39.
Statistical analysis
Statistical significance was calculated using a two-tailed,
unpaired T test. Data considered significant demonstrated p
values less than 0.05.
Supporting Information
Figure S1 DENV-2 does not disrupt endogenous or
exogenous miRNA production. (A) Northern blot on HEK
293s transfected with p124 and infected with the indicated
recombinant DENV-2 viruses at an MOI of 1 48 hpi. Blot was
probed for miR-124 expression (B). Northern blot on HEK293s
and BHKs infected as in (A). Blot was probed for endogenous
levels of miR-93.
(TIF)
Figure S2 Cloning strategy for incorporation of target
sites into the DENV2 39UTR. Site-directed mutagenesis was
performed to generate an AflII restriction enzyme site 7
nucleotides (nt) downstream of the NS5 open reading frame. A
157 nt cassette containing four miR-142 target sites in tandem
were cloned into the AflII site to generate a miR-142-targeted
DENV-2 virus (142t). Viruses containing the same cassette in
reverse and no insertions were also generated to serve as controls
(ctrl and wt viruses, respectively).
(TIF)
Figure S3 Recombinant DENV2 viruses grow to similar
titers in mosquito cells. Multicycle replication kinetics was
performed in C6/36 cells for the indicated time points.
(TIF)
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PLoS Pathogens | www.plospathogens.org 8 January 2012 | Volume 8 | Issue 1 | e1002465Figure S4 In vivo knockdown of miR-142-targeted
DENV-2. (A) Quantitative RT-PCR (qRT-PCR) on Capsid and
tubulin for CD45
+ and CD45
2 cells from splenocytes of Ifnar1
2/2
/Il28r
2/2 mice inoculated with either ctrl or 142t strains via
intravenous (IV) injection for 24 hrs. (B) Viral titers from livers of
Ifnar1
2/2/Il28r
2/2 mice inoculated with either ctrl or 142t strains
via IV injection for 24, 48, and 72 hpi. Each dot represents one
animal.
(TIF)
Figure S5 In vitro escape mutants of miR-142-targeted
DENV-2. (A) RT-PCR on RNA derived from BHKs transfected
with varying amounts of p142, and infected with either ctrl or 142t
viruses. (B) Mutations identified in p142-transfected BHKs
infected with ctrl and 142t viruses. Depicted mutations map to
miR-142 complementary sites in the targeted and untargeted
orientations. Notations in red designate nucleotide changes.
(TIF)
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